A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data.

Yancopoulos, Regeneron’s chief scientific officer ... technologies to deliver the first FDA-approved recombinant monoclonal antibody treatment for any viral disease, and they picked one of ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

We are the only RSV MAB with real world data showing greater ... primarily due to the absence of COVID revenues in 2024. Excluding this COVID impact, our gross margin increased by 0.8%.

SNY earnings call for the period ending December 31, 2024.

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...

Regeneron reported Q4 2024 earnings today - revenues were up 10% YoY to $3.79bn. Full-year revenues were up 8% to $14.2bn. Q4 GAAP EPS at $8.06, and $38 adj. full-year. The company declared its ...

Higher levels of long COVID were found in lower-income households. More than 1 million children may have been affected by long COVID as of 2023, new federal data published Monday suggests.